Repros Therapeutics Inc. (NASDAQ: RPRX) has more than doubled this morning on the heels of yesterday;s report that Androxal® restores normal sperm counts while increasing testosterone levels in hypogonadal men. In short, this is being treated by traders as a potential fertilization clinic killer when it comes to the issue being on the men. At 8:52 AM EST we have seen some 2.2 millioin shares trade hands with the stock up over 150%. The shares are around $2.40 and the close yesterday was $0.89. Average volume is only 1.4 million shares and the 52-week range is $0.65 to $13.94. JON OGG
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment